BioSyntech Appoints Chief Executive Officer

    LAVAL, QC, Aug. 14 /CNW/ - BioSyntech, Inc. (TSX: BSY) a biotechnology
company developing biotherapeutic thermogels for regenerative medicine, today
announced that it has appointed Ms. Jeanne Bertonis, MBA, M.Sc., to the role
of Chief Executive Officer. The Company previously announced that Ms. Bertonis
was retained by BioSyntech as a consultant to assist the Company with its
research and development, regulatory, strategic planning and business
development strategies.
    "Ms. Bertonis has 25 years of experience in the device, drug and
biomaterials industries making her ideally suited to lead BioSyntech to
achieve its commercialization objectives for our lead product for cartilage
repair, BST-CarGel(R)," said Dr. Joyce Tsang, Director and Chair of the
Governance Committee of BioSyntech. "Since joining the Company, she has worked
effectively with BioSyntech as a consultant drawing on her extensive
experience in the medical device sector and we are pleased that she will take
a larger role in development of our Company as we look forward to the final
results for our BST-CarGel(R) trial."
    "It has been my great pleasure this last month to work closely with the
talented team of employees at BioSyntech," said Ms. Jeanne Bertonis, Chief
Executive Officer for BioSyntech. "I've been highly impressed with the
clinical data that has been generated to date, and with the continued support
of the Board of Directors I look forward to implementing the strategic
initiatives that will be developed as a result of the work
PricewaterhouseCoopers is conducting."
    Ms Bertonis has been a management consultant for the last three years,
providing strategic and business advice primarily to venture capital groups
and private biomedical companies, with a focus on biomaterials, cardiovascular
and orthopedics industries. She held the positions of Chief Business Officer
and Vice President, Corporate Development for Angiotech Pharmaceuticals from
2000-2006, where she oversaw all of its business and corporate development
functions, including mergers and acquisitions, strategic collaborations, and
marketing. Prior to joining Angiotech, she held senior business development
positions at Guidant and Genzyme, working across a broad spectrum of
industries including devices, drugs, combination therapies, gene therapy, cell
therapy and bioactive biomaterials.

    About BioSyntech

    BioSyntech is a medical device Company specialized in the development,
manufacturing and commercialization of advanced biotherapeutic thermogels for
regenerative medicine (tissue repair) and therapeutic delivery. Biosyntech's
platform technology is a family of hydrogels called BST-Gel(R), some of which
are liquid at low temperature and solid at human body temperature. These gels
can be injected or applied to a specific local site and offer beneficial
properties for the local repair of damaged tissue such as cartilage, bone and
chronic wounds and provide the benefit of avoiding invasive surgery. The
Company's lead, late-stage product, BST-CarGel(R) is currently undergoing an
international pivotal trial. For additional information, visit

    Forward-Looking Statements

    This press release contains forward-looking statements and information
which are subject to material risks and uncertainties. Such statements are not
historical facts and are based on the current expectations of management. You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause actual results, future circumstances, or events
to differ materially from those projected in the forward-looking information.
These risks include, but are not limited to, those associated with our
capacity to finance our activities, the adequacy, timing, and results of our
clinical trials, the regulatory approval process, competition, securing and
maintaining corporate alliances, market acceptance of the Company's products,
the availability of government and insurance reimbursements for the Company's
products, the strength of intellectual property, the success of research and
development programs, reliance on subcontractors and key personnel, and other
risks and uncertainties detailed from time-to-time in our filings with the
Canadian securities commissions.
    Readers should not place undue reliance on the forward-looking
information, given that (i) our actual results could differ materially from a
conclusion, forecast or projection in the forward-looking information, and
(ii) certain material factors or assumptions which were applied in drawing a
conclusion or making a forecast or projection as reflected in the
forward-looking information, could prove to be inaccurate. Additional
information about (i) the material factors that could cause actual results to
differ materially from the conclusion, forecast or projection in the
forward-looking information, and (ii) the material factors or assumptions that
were applied in drawing a conclusion or making a forecast or projection as
reflected in the forward-looking information, is contained in the Company's
annual report and other documents filed from time to time with the Canadian
securities commissions which are available at These statements
speak only as of the date they are made, and we assume no obligation to revise
such statements as a result of any event, circumstance or otherwise, except in
accordance with law.

    %SEDAR: 00020217EF

For further information:

For further information: James Smith, The Equicom Group, (416) 815-0700

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890